Mexico’s Supreme Court has upheld a 2010 resolution by the Federal Competition Commission (Now COFECE), which imposed sanctions for up to 21 million pesos on several pharmaceutical companies accused of price fixing.
The companies have been accused of coordinating to manipulate the prices in contests for the provision of insulin, electrolyte and saline solution to Mexico’s national health service. The decision marks the first time the court has confirmed the existence of absolute monopolistic behavior.
The court upheld the validity of the economic analysis used to determine the existence price-fixing agreements between the companies, and whether these agreements had negatively affected the market dynamics, equilibrium, or otherwise been detrimental to competition.
Full content: El Diario
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Plaintiffs Seek Communications In Antitrust Case Against Pioneer
May 9, 2024 by
CPI
UK Government Approves Vodafone-Hutchison Merger
May 9, 2024 by
CPI
Senate Majority Leader Announces Plan for AI Regulation Framework
May 9, 2024 by
CPI
BBVA Initiates Aggressive Takeover Bid for Sabadell
May 9, 2024 by
CPI
TikTok to Label AI-Generated Content Amid Election Interference Concerns
May 9, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI